Posted by Michael Wonder on 20 Feb 2020
FDA works to ensure smooth regulatory transition of insulin and other biological products
20 February 2020 - Transition is expected to increase patient access and potentially lower prices on insulin.
Today, the U.S. Food and Drug Administration took additional steps to ensure a smooth regulatory transition aimed at increasing patient access to insulin products used daily by millions of Americans to maintain stable blood glucose levels, as well as certain other biological products set to transition regulatory pathways in March.
Today’s actions include publishing a final rule and additional resources to provide useful information to stakeholders, including industry, patients and health care providers.
